NCT05253495RecruitingPhase 2
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Reducing the Burden of Oncologic Chemoradiotherapy And Radiation Exposure From Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults With Lymphoma
Source: ClinicalTrials.gov · Last updated 13 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 14 Feb 2022
- Start date
- 1 Feb 2022
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- New York Medical College
- Diseases
- Hodgkin lymphoma, Childhood cancers
- NCT number
- NCT05253495
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From 1 Feb 2022 to the primary completion date, 31 Dec 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
Other
- Primary mediastinal B-cell lymphoma (PMBL)
- T-cell/histiocyte-rich large B-cell lymphoma
- Gray zone lymphoma
- Follicular lymphoma
- Posttransplant lymphoproliferative lymphoma (PTLD)
Who the study is looking for
- Newly diagnosed patients with histologically or cytologically proven newly diagnosed MB-NHL or cHL according to WHO Classification who meet the following criteria are eligible:
- COHORT I:
- Burkitt lymphoma (ICD-O 9687/3) Burkitt-like lymphoma with 11q aberration (ICD-O 9687/3) Diffuse large B-cell lymphoma, NOS (ICD-O 9680/3) High grade B-cell lymphoma (ICD-O 9680/3)
- COHORT Ia: stage III with LDH ≥ 2 ULN OR stage IV (5-24% bone marrow lymphoma infiltration) (GROUP B)61
- COHORT Ib: any CNS involvement and/or BM involvement (≥ 25% lymphoma cells) (GROUP C)61 OR patients with less than 20% tumor size reduction post chemotherapy with cyclophosphamide, dexamethasone, vincristine (DOC Reduction for Cohort Ia).
- COHORT II Classical Hodgkin lymphoma (ICD-O 9650/3, 9663/3, 9651/3, 9652/3, 9653/3)
- COHORT IIa: stage I-IIA with bulky ± E, I-IIB no bulky ± E, IIIA ± E (INTERMEDIATE RISK)
- COHORT IIb: stage IIB with bulky ± E, IIIA with bulky ± E, IIIB, IV (HIGH RISK)
- Adequate organ function
Age in the registry: 3 years to 39 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama Coordinator of this site? Confirm its status | Birmingham | United States | Not yet recruiting |
| University of Flordia Coordinator of this site? Confirm its status | Gainsville | United States | Recruiting |
| New York Medical College Coordinator of this site? Confirm its status | Vallhala | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.